{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-301777","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2023-12-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.315253+00:00","generated_at":"2026-06-07T08:07:56.359655+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AlloVir discontinues all three Phase 3 posoleucel trials after DSMB futility analyses","bullets":["Three Phase 3 trials for prevention, hemorrhagic cystitis, and adenovirus stopped after separate DSMBs deemed each unlikely to meet primary endpoints.","No safety concerns observed; discontinuation based on pre-planned futility analyses.","Company to prioritize capital preservation; held $213.3M cash and equivalents as of Sep 30, 2023.","AlloVir will review strategic alternatives including merger, sale, or licensing of assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-301777","json":"https://secwatch.observer/filing/0001193125-23-301777.json","markdown":"https://secwatch.observer/filing/0001193125-23-301777.md","text":"https://secwatch.observer/filing/0001193125-23-301777.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/0001193125-23-301777-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312523301777/d671953d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T08:07:56.359655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}